Supporting Information

Systematic Synthesis of Novel Phosphoglycolipid Analogues as Potential Agonists of GPR55

Junpei Abe, Adam T. Guy, Feiqing Ding, Peter Greimel, Yoshio Hirabayashi, Hiroyuki Kamiguchi and Yukishige Ito

- 1. Biological experiments Materials and methods
- 2. Chemical experiments
 - 2-1. General procedures
 - 2-2. Synthesis and compound characterization
 - 2-3. ¹H and ¹³C NMR chart of compounds

1. Biological experiments - Materials and methods

Animals

All animal experiment protocols were reviewed and approved by the Wako Animal Experiments Committee at RIKEN. Fertilized Boris Brown chicken eggs were purchased from a local supplier (Inoue Poultry Farm, Sagamihara, Japan) and incubated in a rocking egg incubator at 38 °C until the embryos had developed to Hamburger and Hamilton Stage 36 (*Hamburger and Hamilton*, 1951).

Cell culture

Neuronal cell culture was carried out as previously described (*Guy et al.*, 2019). Dorsal root ganglia (DRG) were dissected from Stage 36 embryos and DRG sensory neurons were extracted and dissociated into single cells by trypsinization. Dissociated neurons were suspended in Leibowitz's L15 medium (Life Technologies, CA) with N2 Supplement (Life Technologies), 20 ng/ml nerve growth factor (NGF; Promega, WI) and 750 µg/ml bovine serum albumin (Life Technologies), and seeded onto 3 cm glass-based dishes that had been coated with 9 µg/cm² mouse laminin (Life Technologies). Seeded dishes were placed in a 37 °C incubator with 5% CO₂ for 1 – 4 hours before use in the turning assay.

In vitro axon turning assay

Axon turning assays (Lohof et al., 1992) were performed as described previously (Guy et al., 2019) with some modifications. Test compounds were dissolved in a vehicle of 0.001% (v/v) DMSO/PBS and used at an in-pipette concentration of 20 µM. On an Olympus IX51 inverted microscope (Olympus Corporation, Tokyo, Japan), a growth cone, the tip of single extending axons, was introduced to a microscopic concentration gradient of test compounds and imaged for 45 minutes using a QICAM Fast 1394 (QImaging, Burnaby, Canada) CCD digital camera controlled by Metavue software (version 7.8.2.0, Molecular Devices, CA). This microscopic concentration gradient was produced by repeated pulsatile ejection of test compound solution through a glass micropipette (borosilicate glass with filament, catalog # BF100-50-10, Sutter Instrument, CA) the tip of which was placed 100 µm away from the growth cone at an angle of 45°. Micropipettes were made using a P-97 Flaming/Brown micropipette puller (Sutter Instrument), designed to have a steep shoulder and an approximate tip diameter of approximately 1 μ m. Nitrogen gas pressure of 1 – 4 psi was applied to the test solution within the pipette by connection to a PV820 Picopump (World Precision Instruments, FL) electrically gated pressure control system. The frequency (2 Hz) and duration (20 ms) of positive gas pressure was controlled by a pulse generator (model AWG-50, ELMOS, Osaka, Japan). This pulsatile ejection of test solution from the pipette tip induces and maintains a microscopic concentration gradient of test compound in the culture medium for the

duration of the assay (*Lohof et al*, 1992, *Zheng et al*, 1994). At a distance of 100 μ m from the pipette tip, test compound concentration is approximately 1000 times lower than the in-pipette concentration ((*Lohof et al*, 1992, *Ming et al*, 1997). At the end of the assay, the turning angle (the angle between the growth cone's starting position and its final position, measured relative to its axon) and axon extension (in microns) were calculated using Metavue software. Growth cones that bifurcated, collapsed, retracted or failed to extend more than 10 μ m during the 45 minutes of the assay were discounted from the study.



Figure S. Axon growth is unaffected by treatment with LPGlc analogues. Bars show mean axon extension in microns \pm SEM, numbers in parentheses indicate the number of axons tested. No significant difference in axon extension was observed.

Methods References

- Guy A. T.; Kano K.; Ohyama J.; Kamiguchi K.; Hirabayashi Y.; Ito Y.; Matuso I.; Greimel P. Preference For Glucose Over Inositol Head Group During Lysolipid Activation of G Protein-Coupled Receptor 55. ACS Chem. Neuro. 2019, 10(1):716–727.
- [2] Hamburger, V.; Hamilton, H. L. A Series of Normal Stages in the Development of the Chick Embryo. J. Morphol. 1951, 88 (1), 49–92.
- [3] Lohof, A. M.; Quillan, M.; Dan, Y.; Poo, M. M. Asymmetric Modulation of Cytosolic cAMP Activity Induces Growth Cone Turning. J. Neurosci. 1992, 12 (4), 1253–1261.
- [4] Ming, G. L.; Song, H. J.; Berninger, B.; Holt, C. E.; Tessier-Lavigne, M.; Poo, M. M. cAMP-Dependent Growth Cone Guidance by Netrin-1. *Neuron* **1997**, *19* (6), 1225–1235.
- [5] Zheng, J. Q.; Felder, M.; Connor, J. A.; Poo, M. M. Turning of Nerve Growth Cones Induced by Neurotransmitters. *Nature* 1994, 368 (6467), 140–144.

2. Chemical experiments and compound characterization

2-1. General procedures

Air and/or moisture sensitive reactions were carried out under argon atmosphere with anhydrous solvents. Reactions were monitored by thin-layer chromatography (TLC) (Kieselgel 60 F254, EM Science). Compounds were detected by UV light and/or Hanessian's stain and purified by column chromatography (silica gel 60, 40-100 mesh, EM Science). Solvents were removed lower than 40 °C under reduced pressure. Synthesized compounds were analyzed by ¹H NMR and ¹³C NMR (JEOL ECX 400 spectrometer). ¹H NMR analyses were conducted with CDCl₃, CD₃OD or pyridine-d₅ referenced to CHCl₃ at 7.26 ppm, to CD₃OD at 3.31 ppm or to pyridine at 7.22 ppm, respectively. ¹³C NMR analyses were referenced to CDCl₃ at 77.0 ppm, CD₃OD at 49.00 or pyridine-d₅ at 123.87 ppm. Synthesized compounds were assigned by standard 2D experiments. MALDI-TOF mass spectra were recorded on a SHIMADZU Compact MALDI AXIMA-CFR spectrometer with 2,5-dihydroxybenzoic acid (DHBA) as the matrix. HRMS determinations were performed with a JEOL Accustom JMS-T700LCK mass spectrometer with CF₃CO₂Na as the internal standard. All other reagents were purchased from Kanto Chemicals Co. Inc., Tokyo Chemical Industries Co., Ltd., FUJIFILM Wako Pure Chemical Co., Aldrich Chemical Co. and Avanti Polar Lipids, Inc.

2-2. Synthesis and compound characterization

10-(Benzyloxy)decan-1-ol (13a)

To a suspension of 1,10-decanediol (**12a**) (857 mg, 4.92 mmol) and sodium hydride (197 mg, 4.92 mmol) in dry DMF (16 mL) was added benzyl bromide (195 μ L, 1.64 mmol). The mixture was stirred at 60 °C for 21 h. The reaction was quenched with water and the mixture was diluted with EtOAc followed by washing with brine three times and then dried over Na₂SO₄. After filtration and evaporation under reduced pressure, the crude product was purified using column chromatography (silica gel, hexane / EtOAc = 8 / 1) to afford **13a** (colorless oil, 173 mg, 40% yield). ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.26 (m, 5H), 4.50 (s, 2H), 3.63 (t, *J* = 6.7 Hz, 2H), 3.46 (t, *J* = 6.7 Hz, 2H), 1.64-1.52 (m, 4H), 1.38-1.26 (m, 12H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.6, 128.3, 127.6, 127.4, 72.8, 70.4, 63.0, 32.7, 29.7, 29.4, 29.4, 29.4, 29.3, 26.1, 25.6; HRMS (ESI) m/z [M+Na]⁺ calculated for C₁₇H₂₈O₂Na 287.1982, found 287.1989

(((10-Bromodecyl)oxy)methyl)benzene (14a)

To a solution of **13a** (269 mg, 1.02 mmol) and tetrabromomethane (677 mg, 2.04 mmol) in dry THF (5 mL) was added triphenylphosphine (535 mg, 2.04 mmol). The mixture was stirred at ambient temperature for 2 h. After evaporation under reduced pressure, the crude product was purified using column chromatography (silica gel, hexane to hexane / EtOAc = 8 /1) to afford **14a** (yellow oil, 332 mg, 99%). ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.35 (m, 4H), 7.31-7.27 (m, 1H), 4.51 (s, 2H), 3.47 (t, *J* = 6.7, 2H), 3.41 (t, *J* = 7.2, 2H), 1.89-1.82 (m, 2H), 1.66-1.59 (m, 2H), 1.44-1.30 (m, 12H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.5, 128.2, 127.4, 127.3, 72.7, 70.3, 33.8, 32.7, 29.6, 29.3, 29.3, 29.2, 28.6, 28.0, 26.0; HRMS (ESI) m/z [M+Na]⁺ calculated for C₁₇H₂₇BrONa 349.1143, 351.1123 found 349.1146, 351.1122

(S)-2-(3-((10-(Benzyloxy)decyl)thio)-2-((*tert*-butyldimethylsilyl)oxy)propyl)isoindoline-1,3-dion e (19a)

To a solution of **18**^[1] (135 mg, 0.384 mmol) and sodium hydride (18.0 mg, 0.461 mmol) in dry DMF (0.9 mL) at 0 °C under argon atmosphere was added a solution of **14a** (151 mg, 0.461 mmol) in dry DMF (1.0 mL). The mixture was stirred at ambient temperature for 8 h. The reaction was quenched with water at 0 °C and the mixture was diluted with EtOAc, followed by washing with brine three times and then dried over Na₂SO₄. After filtration and evaporation under reduced pressure, the crude product was purified using column chromatography (silica gel, hexane / EtOAc = 8 /1) to afford **19a** (yellow oil, 174 mg, 78% yield). $[\alpha]_D^{26} = -26.6$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.83 (m, 2H), 7.74-7.70 (m, 2H), 7.36-7.26 (m, 4H), 4.50 (s, 2H), 4.17 (m, 1H), 3.93-3.78 (m, 2H), 3.46 (t, *J* = 6.7 Hz, 2H), 2.68-2.52 (m, 4H), 1.64-1.52 (m, 4H),

1.39-1.25 (m, 12H), 0.81 (s, 9H), 0.050 (s, 3H), -0.12 (s, 3H) ; 13 C NMR (CDCl₃, 100 MHz): δ 168.2, 138.6, 133.9, 132.0, 128.3, 127.6, 127.4, 123.1, 72.8, 70.5, 69.1, 43.1, 37.4, 33.0, 29.7, 29.6, 29.5, 29.4, 29.2, 28.8, 17.7, -4.6, -4.9; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₄H₅₁NO₄SSiNa 620.3206, found 620.3199

(S)-2-(3-((10-(Benzyloxy)decyl)thio)-2-hydroxypropyl)isoindoline-1,3-dione (20a)

20a (yellow oil, 154 mg, 83% yield) was synthesized from **19a** (227 mg, 0.366 mmol) in the reported method.^[1] $[\alpha]_D^{26} = 5.20$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.88-7.84 (m, 2H), 7.75-7.72 (m, 2H), 7.35-7.26 (m, 5H), 4.50 (s, 2H), 4.03 (m, 1H), 3.86 (m, 2H), 3.46 (t, *J* = 6.7 Hz, 3H), 2.82-2.51 (m, 4H), 1.64-1.53 (m, 4H), 1.38-1.24 (m, 12H) ; ¹³C NMR (CDCl₃, 100 MHz): δ 168.6, 138.6, 134.1, 131.9, 128.3, 127.6, 127.4, 123.4, 72.8, 70.4, 68.2, 42.9, 37.5, 32.6, 29.7, 29.6, 29.4, 29.4, 29.1, 28.7, 26.1; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₈H₃₇O₄SNa 506.2340, found 506.2341

(S)-1-Amino-3-((10-(benzyloxy)decyl)thio)propan-2-ol (21a)

To a solution of **20a** (114 mg, 0.236 mmol) in MeOH (2.4 mL) was added hydrazine monohydrate (57.0 μ L, 1.18 mmol). The mixture was stirred under reflux for 2 h. After evaporation under reduced pressure, 2 N aq. K₂CO₃ (236 μ L) and H₂O (2 mL) were added to the mixture and then the crude product was extracted with CHCl₃ three times and dried over Na₂SO₄. After filtration and evaporation under reduced pressure, **21a** was obtained (white solid, 69.0 mg, 69% yield). **21a** was used for next step without further purification. ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.23 (m, 5H), 4.49 (s, 2H), 3.64 (m, 1H), 3.45 (t, *J* = 6.7 Hz, 2H), 2.87 (m, 1H), 2.70-2.61 (m, 2H), 2.61-2.50 (m, 3H), 1.64-1.53 (m, 4H), 1.40-1.24 (m, 12H) ; ¹³C NMR (CDCl₃, 100 MHz): δ 138.5, 128.2, 127.5, 127.3, 72.7, 70.4, 46.3, 37.0, 32.4, 29.6, 29.6, 29.4, 29.3, 29.0, 28.7, 26.0; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₀H₃₆NO₂S 354.2464, found 354.2467

3-(((S)-3-((10-(Benzyloxy)decyl)thio)-2-hydroxypropyl)amino)-4-(glucosylamino)cyclobut-3-en e-1,2-dione (11a)

To a solution of **28a**^[1] (19.0 mg, 0.0636 mmol) and **21a** (22.5 mg, 0.0636 mmol) in EtOH (636 µL) was added DIPEA (11.0 µL, 0.0636 mmol). The mixture was stirred at ambient temperature overnight. After evaporation under reduced pressure, the crude product was purified using column chromatography (silica gel, chloroform / methanol = $10 / 1 \rightarrow 5 / 1$) to afford **11a** (white solid, 25.0 mg, 64% yield). [α]_D²⁶ = -37.4 (c 1.0 in pyridine); ¹H NMR (pyridine-d₅, 400 MHz): δ 7.49 (d, *J* = 7.2 Hz, 2H), 7.40 (m, 2H), 7.32 (t, *J* = 7.2 Hz, 2H), 4.55-4.50 (m, 3H), 4.43-3.97 (m, 7H), 3.48 (t, *J* = 6.7 Hz, 2H), 2.94 (d, *J* = 6.3 Hz, 2H), 2.64 (t, *J* = 7.2 Hz, 2H), 1.68-1.51 (m, 4H), 1.41-1.14 (m, 14H); ¹³C NMR (pyridine-d₅, 100 MHz): δ 186.4, 184.7, 170.7, 169.4, 140.0, 129.0, 128.3, 128.1,

86.3, 80.7, 79.1, 75.7, 73.2, 71.4, 71.2, 71.0, 62.0, 50.0, 37.8, 33.3, 30.5, 30.3, 30.1, 30.0, 30.0, 29.8, 29.4, 26.8; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₀H₄₆N₂O₉SNa 633.2822, found 633.2825

1,13-Tridecanediol (12b)

To a solution of lithium aluminum hydride (LAH) (2.8 g, 0.0738 mol) in dry THF (246 mL) on ice bath was slowly added tridecanedioic acid (3.0 g, 0.0123 mol). The mixture was stirred under reflux for 5.5 h, followed by quenching with water and 1 N aq. NaOH on ice bath. The crude product was extracted with EtOAc three times and dried over Na₂SO₄. After filtration and evaporation under reduced pressure, **12b** was obtained (white solid, 2.56 g, 97% yield). ¹H NMR (CDCl₃, 400 MHz): δ 3.63 (t, *J* = 6.7 Hz, 4H), 1.58 (m, 4H), 1.50-1.20 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ 63.0, 32.7, 29.5, 29.5, 29.3, 25.7; HRMS (ESI) m/z [M+Na]⁺ calculated for C₁₃H₂₈O₂Na 239.1987, found 239.1991

13-(Benzyloxy)tridecan-1-ol (13b)

13b (colorless oil, 254 mg, 60% yield) was synthesized from **12b** (308 mg, 1.29 mmol) in the same manner as **13a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.34-7.33 (m, 4H), 7.29-7.27 (m, 1H), 4.49 (s, 2H), 3.56 (t, *J* = 6.7, 2H), 3.46 (t, *J* = 7.2, 2H), 1.66-1.59 (m, 2H), 1.57-1.50 (m, 2H), 1.38-1.28 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.3, 128.0, 127.4, 127.2, 72.6, 70.2, 62.4, 32.5, 29.5, 29.4, 29.4, 29.2, 25.9, 25.6; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₀H₃₄O₂Na 329.2456, found 329.2455

(((13-Bromotridecyl)oxy)methyl)benzene (14b)

14b (colorless oil, 516 mg, 85% yield) was synthesized from **13b** (511 mg, 1.55 mmol) in the same manner as **14a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.34 (m, 4H), 7.31-7.27 (m, 1H), 4.51 (s, 2H), 3.47 (t, *J* = 6.7 Hz, 2H), 3.41 (t, *J* = 7.2 Hz, 2H), 1.89-1.82 (m, 2H), 1.65-1.58 (m, 2H), 1.44-1.27 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.6, 128.3, 127.6, 127.4, 72.8, 70.5, 34.0, 32.8, 29.7, 29.5, 29.5, 29.4, 29.4, 28.7, 28.1, 26.1; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₀H₃₃BrONa 391.1612, 393.1592, found 391.1609, 393.1587

(S)-2-(3-((13-(Benzyloxy)tridecyl)thio)-2-((*tert*-butyldimethylsilyl)oxy)propyl)isoindoline-1,3-di one (19b)

19b (colorless oil, 611 mg, 75% yield) was synthesized from **14b** (578 mg, 1.48 mmol) and in the same manner as **19a**. $[\alpha]_D^{26} = -35.8$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.80 (m, 2H), 7.73-7.68 (m, 2H), 7.37-7.23 (m, 5H), 4.49 (s, 2H), 4.17 (m, 1H), 3.93-3.78 (m, 2H), 3.46 (t, *J* = 6.7 Hz, 2H), 2.68-2.52 (m, 4H), 1.64-1.52 (m, 4H), 1.39-1.25 (m, 18H), 0.80 (s, 9H), 0.048 (s, 3H), -0.12 (s, 3H) ; ¹³C NMR (CDCl₃, 100 MHz): δ 168.2, 138.6, 133.8, 132.0, 128.2, 127.5, 127.4, 123.1, 72.7, 70.4, 69.1, 43.1, 37.4, 32.9, 29.7, 29.6, 29.5, 29.4, 29.1, 28.8, 26.1, 25.5, 17.7, -4.7, -5.0;

HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₇H₅₇NO₄SSiNa 662.3675, found 662.3671

(S)-2-(3-((13-(Benzyloxy)tridecyl)thio)-2-hydroxypropyl)isoindoline-1,3-dione (20b)

20b (colorless oil, 386 mg, 57% yield) was synthesized from **19b** (818 mg, 1.24 mmol) in the same manner as **20a**. $[\alpha]_D^{26} = 3.40$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.82 (m, 2H), 7.72-7.69 (m, 2H), 7.34-7.32 (m, 4H), 7.29-7.27 (m, 1H), 4.50 (s, 2H), 4.05 (m, 1H), 3.86-3.83 (m, 2H), 3.46 (t, *J* = 6,7 Hz, 2H), 2.77-2.54 (m, 4H), 1.65-1.54 (m, 4H), 1.41-1.24 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.4, 138.5, 133.9, 131.7, 128.1, 127.4, 127.2, 123.2, 72.6, 70.3, 68.1, 42.8, 37.2, 32.4, 29.6, 29.5, 29.4, 29.3, 29.3, 29.0, 28.6, 26.0; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₁H₄₄NO₄S 526.2991, found 526.2989

(S)-1-Amino-3-((13-(benzyloxy)tridecyl)thio)propan-2-ol (21b)

21b (white solid, 58.0 mg, quant.) was synthesized from **20b** (76.0 mg, 0.139 mmol) in the same manner as **21a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.36-7.32 (m, 4H), 7.29-7.25 (m, 1H), 4.49 (s, 2H), 3.63 (m, 2H), 3.45 (t, *J* = 6.7 Hz, 2H), 2.87 (dd, *J* = 3.6, 13 Hz, 1H), 2.71-2.50 (m, 5H),1.60 (m, 4H), 1.40-1.23 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.6, 128.2, 127.5, 127.4, 72.7, 70.4, 46.4, 37.0, 32.4, 29.7, 29.6, 29.5, 29.4, 29.4, 29.1, 28.8, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₃H₄₂NO₂S 396.2936, found 396.2932

3-(((S)-3-((13-(Benzyloxy)tridecyl)thio)-2-hydroxypropyl)amino)-4-(glucosylamino)cyclobut-3ene-1,2-dione (11b)

11b (white solid, 37.0 mg, 88% yield) was synthesized from **21b** (25.9 mg, 0.0619 mmol) in the same manner as **11a**. $[\alpha]_D^{26} = -56.8$ (c 1.0 in pyridine); ¹H NMR (pyrdine-d₅, 400 MHz): δ 7.49 (d, *J* = 7.6 Hz, 2H), 7.40 (t, *J* = 7.2 Hz, 2H), 7.32 (t, *J* = 7.2 Hz, 1H), 4.55-4.50 (m, 3H), 4.41-3.95 (m, 7H), 3.49 (t, *J* = 6.3 Hz, 2H), 2.93 (d, *J* = 6.3 Hz, 2H), 2.64 (t, *J* = 7.6 Hz, 2H), 1.70-1.54 (m, 4H), 1.45-1.17 (m, 20H); ¹³C NMR (pyrdine-d₅, 100 MHz): δ 186.3, 184.7, 170.7, 169.4, 140.0, 129.0, 128.2, 128.0, 86.3, 80.7, 79.1, 75.7, 73.2, 71.5, 71.3, 71.0, 62.0, 50.0, 37.8, 33.3, 30.5, 30.3, 30.2, 30.1, 30.1, 29.8, 29.5, 26.9; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₃H₅₃N₂O₉S 653.3472, found 653.3474

1,15-Pentadecanediol (12c)

12c (white solid, 4.17 g, quant.) was synthesized from 15-pentadecanolactone (3.75 g, 0.0156 mol) in the same manner as **12a**. ¹H NMR (CDCl₃, 400 MHz): δ 3.63 (t, *J* = 6.7 Hz, 4H), 1.57 (m, 4H), 1.40-1.10 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz) δ 63.0, 32.7, 29.5, 29.5, 29.5, 29.4, 25.7; HRMS (ESI) m/z [M+Na]⁺ calculated for C₁₅H₃₂O₂Na 267.2300, found 267.2300

15-(Benzyloxy)pentadecan-1-ol (13c)

13c (colorless oil, 274 mg, 24% yield) was synthesized from **12c** (205 mg, 0.767 mmol) in the same manner as **13a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.34-7.33 (m, 4H), 7.30-7.27 (m, 1H), 4.50 (s, 2H), 3.63 (t, *J* = 6.3 Hz, 2H), 3.46 (t, *J* = 6.7 Hz, 2H), 1.65-1.53 (m, 4H), 1.40-1.26 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.7, 128.3, 127.6, 127.4, 72.8, 70.5, 63.0, 32.7, 29.7, 29.6, 29.5, 29.4, 29.4, 26.1, 25.7; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₂H₃₈O₂Na 357.2770, found 357.2762

(((15-Bromopentadecyl)oxy)methyl)benzene (14c)

14c (colorless oil, 197 mg, 68% yield) was synthesized from **13c** (247 mg, 0.691 mmol) in the same manner as **14a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.38-7.35 (m, 4H), 7.31-7.27 (m, 1H), 4.51 (s, 2H), 3.48 (t, J = 6.7 Hz, 2H), 3.41 (t, J = 6.7 Hz, 2H), 1.90-1.83 (m, 2H), 1.66-1.59 (m, 2H), 1.45-1.28 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.7, 128.2, 127.4, 72.8, 70.5, 33.9, 32.8, 29.7, 29.6, 29.5, 29.5, 29.4, 29.4, 28.7, 28.1, 26.1; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₂H₃₇BrONa 419.1925, 421.1905 found 419.1928, 421.1908

(S)-2-(3-((15-(Benzyloxy)pentadecyl)thio)-2-((*tert*-butyldimethylsilyl)oxy)propyl)isoindoline-1,3 -dione (19c)

19c (colorless oil, 300 mg, 67% yield) was synthesized from **14c** (182 mg, 0.435 mmol) in the same manner as **19a**. $[\alpha]_D^{26} = -37.2$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.85-7.83 (m, 2H), 7.72-7.70 (m, 2H), 7.34-7.33 (m, 4H), 7.30-7.27 (m, 1H), 4.50 (s, 2H), 4.19-4.16 (m, 1H), 3.93-3.78 (m, 2H), 3.46 (t, *J* = 6.3 Hz, 2H), 2.56 (t, *J* = 7.2 Hz, 2H), 1.64-1.53 (m, 4H), 1.37-1.25 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.6, 133.8, 132.0, 128.2, 127.5, 127.3, 123.0, 72.7, 70.4, 69.1, 29.7, 29.6, 29.5, 29.4, 29.4, 29.1, 28.7, 26.1, 25.5; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₉H₆₁NO₄SSiNa 690.3988, found 690.3981

(S)-2-(3-((15-(Benzyloxy)pentadecyl)thio)-2-hydroxypropyl)isoindoline-1,3-dione (20c)

20c (colorless oil, 113 mg, 49% yield) was synthesized from **19c** (276 mg, 0.400 mmol) in the same manner as **20a**. $[\alpha]_D^{26} = 2.80$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.87-7.84 (m, 2H), 7.75-7.71 (m, 2H), 7.34-7.33 (m, 4H), 7.30-7.27 (m, 1H), 4.50 (s, 2H), 4.03 (m, 1H), 3.86-3.84 (m, 2H), 3.46 (t, *J* = 6.7 Hz, 2H), 2.90 (m, 1H), 2.78-2.73 (m, 1H), 2.63-2.53 (m, 3H), 1.64-1.54 (m, 4H), 1.35-1.25 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.6, 134.0, 131.8, 128.2, 127.5, 127.3, 123.3, 72.7, 70.4, 68.1, 42.9, 37.4, 32.5, 29.6, 29.6, 29.5, 29.4, 29.1, 28.7, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₃H₄₈NO₄S 554.3304, found 554.3303

(S)-1-Amino-3-((15-(benzyloxy)pentadecyl)thio)propan-2-ol (21c)

21c (white solid, 55.0 mg, 94% yield) was synthesized from 20c (75.5 mg, 0.131 mmol) in the

same manner as **21a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.33-7.32 (m, 4H), 7.29-7.23 (m, 1H), 4.49 (s, 2H), 3.63 (m, 1H), 3.45 (t, J = , 2H), 2.89-2.85 (, 1H), 2.69-2.62 (m, 2H), 2.56-2.50 (m, 3H), 1.63-1.53 (m, 4H), 1.35-1.24 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 138.6, 128.2, 127.3, 72.7, 70.4, 46.4, 37.0, 32.4, 29.7, 29.6, 29.5, 29.4, 29.4, 29.1, 28.8, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₅H₄₆NO₂S 424.3249, found 424.3249

3-(((S)-3-((15-(Benzyloxy)pentadecyl)thio)-2-hydroxypropyl)amino)-4-(glucosylamino)cyclobut -3-ene-1,2-dione (11c)

11c (white solid, 41.0 mg, 84% yield) was synthesized from **21c** (30.4 mg, 0.0717 mmol) in the same manner as **11a**. $[\alpha]_D^{26} = -24.0$ (c 1.0 in pyridine); ¹H NMR (pyridine-d₅, 400 MHz): δ 7.49 (d, J = 7.6 Hz, 2H), 7.40 (t, J = 7.2 Hz, 2H), 7.32 (t, J = 7.2 Hz, 2H), 4.55-4.48 (m, 3H), 4.43-3.97 (m, 7H), 3.49 (t, = 6.3 Hz, 2H), 2.93 (d, J = 6.3 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 1.70-1.54 (m, 4H), 1.43-1.18 (m, 24H); ¹³C NMR (pyridine- d₅, 100 MHz): δ 186.3, 184.6, 170.6, 169.4, 140.0, 129.0, 128.2, 128.0, 86.3, 80.6, 79.1, 75.7, 73.2, 71.4, 71.3, 70.9, 62.0, 49.9, 37.8, 33.3, 30.5, 30.3, 30.2, 30.2, 30.2, 30.1, 29.8, 29.5, 26.8; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₅H₅₆N₂O₉SNa 703.3604, found 703.3599

10-(Naphthalen-2-ylmethoxy)decan-1-ol (13d)

13d (white solid, 342 mg, 66% yield) was synthesized from **12a** (857 mg, 4.92 mmol) in the same manner as **13a**.¹H NMR (CDCl₃, 400 MHz): δ 7.85 (m, 2H), 7.79 (s, 1H), 7.48 (m, 3H), 4.68 (s, 2H), 3.62 (t, *J* = 6.7 Hz, 2H), 3.52 (t, *J* = 6.7 Hz, 2H), 1.70-1.61 (m, 2H), 1.59-1.51 (m, 2H), 1.41-1.27 (m, 12H) ; ¹³C NMR (CDCl₃, 100 MHz): δ 136.1, 133.2, 132.8, 128.0, 127.7, 127.6, 126.2, 125.9, 125.6, 72.8, 70.4, 62.9, 32.7, 29.7, 29.4, 29.4, 29.3, 26.1, 25.6; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₁H₃₀O₂Na 337.2143, found 337.2138

2-(((10-Bromodecyl)oxy)methyl)naphthalene (14d)

14d (white solid, 373 mg, 95% yield) was synthesized from **13d** (332 mg, 0.984 mmol) in the same manner as **14a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.81 (m, 3H), 7.80 (s, 1H),7.52-7.45 (m, 3H), 4.68 (s, 2H), 3.52 (t, J = 6.7 Hz), 3.41 (t, J = 6.7 Hz, 2H), 1.85 (m, 2H), 1.65 (m, 2H), 1.48-1.27 (m, 12H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.1, 133.2, 132.8, 128.0, 127.7, 127.6, 126.1, 125.9, 125.6, 72.8, 70.4, 33.9, 32.7, 29.7, 29.3, 29.3, 29.2, 28.6, 28.0, 26.1; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₁H₂₉BrONa 399.1299, 401.1279, found 399.1295, 401.1275

(S)-2-(2-((*tert*-Butyldimethylsidlyl)oxy)-3-((10-(naphthalen-2-ylmethoxy)decyl)thio)propyl)isoin doline-1,3-dione (19d)

19d (yellow oil, 172 mg, 69% yield) was synthesized from 14d (148 mg, 0.371 mmol) in the same

manner as **19a**. $[\alpha]_D^{26} = -24.6$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.85-7.79 (m, 5H), 7.77 (s, 1H), 7.70-7.66 (m, 2H), 7.49-7.43 (m, 3H), 4.66 (s, 2H), 4.19 (m, 1H), 3.94-3.78 (m, 2H), 3.51 (t, *J* = 6.7 Hz, 2H), 2.65 (t, *J* = 7.2 Hz, 2H), 2.56 (t, *J* = 7.2 Hz, 2H), 1.68-1.53 (m, 4H), 1.42-1.23 (m, 12H), 0.817 (s, 9H), 0.0617 (s, 3H), -0.109 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.1, 136.1, 133.8, 133.1, 132.8, 131.9, 127.9, 127.7, 127.5, 126.1, 125.9, 125.6, 123.0, 72.8, 70.4, 69.1, 43.0, 37.3, 32.9, 29.6, 29.5, 29.4, 29.3, 29.1, 28.7, 26.1, 25.5, 17.7, -4.7, -5.0; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₈H₅₄NO₄SSi 648.3543, found 648.3539

(S)-2-(2-Hydroxy-3-((10-(naphthalen-2-ylmethoxy)decyl)thio)propyl)isoindoline-1,3-dione (20d)

20d (yellow oil, 127 mg, 90% yield) was synthesized from **19d** (170 mg, 0.254 mmol) in the same manner as **20a**. $[\alpha]_D^{26} = 2.60$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.80 (m, 5H), 7.77 (s, 1H), 7.72-7.67 (m, 2H), 7.48-7.44 (m, 3H), 4.66 (s, 2H), 4.03 (m, 1H), 3.83 (d, *J* = 4.9 Hz, 2H), 3.50 (t, *J* = 6.7 Hz, 2H), 2.98 (br, 1H), 2.77-2.57 (m, 2H), 2.54 (t, *J* = 7.2 Hz, 2H), 1.67-1.53 (m, 4H), 1.41-1.23 (m, 12H) ; ¹³C NMR (CDCl₃, 100 MHz): δ 168.5, 136.1, 134.0, 133.1, 132.8, 131.8, 128.0, 127.7, 127.6, 126.1, 125.9, 125.6, 125.6, 123.3, 72.8, 70.4, 68.1, 42.8, 37.4, 32.5, 29.6, 29.6, 29.4, 29.3, 29.0, 28.7, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₂H₄₀NO₄S 534.2678, found 534.2674

(S)-1-Amino-3-((10-(naphthalen-2-ylmethoxy)decyl)thio)propan-2-ol (21d)

21d (yellow solid, 94.0 mg, 72% yield) was synthesized from **20d** (170 mg, 0.306 mmol) in the same manner as **21a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.85-7.80 (m, 3H), 7.78 (s, 1H), 7.49-7.44 (m, 3H), 4.66 (s, 2H), 3.66 (m, 1H), 3.50 (t, *J* = 6.7 Hz, 2H), 2.90 (dd, *J* = 3.2, 13 Hz, 2H), 2.72-2.55 (m, 2H), 2.52 (t, *J* = 7.2 Hz, 2H), 1.67-1.53 (m, 4H), 1.41-1.23 (m, 12H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.1, 133.2, 132.8, 128.0, 127.7, 127.6, 126.1, 125.9, 125.6, 72.8, 70.4, 70.2, 46.2, 37.0, 32.4, 29.7, 29.6, 29.4, 29.3, 29.1, 28.7, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₄H₃₈NO₂S 404.2623, found 404.2620

3-(((S)-2-Hydroxy-3-((10-(naphthalen-2-ylmethoxy)decyl)thio)propyl)amino)-4-(glucosylamino)cyclobut-3-ene-1,2-dione (11d)

11d (white solid, 15.0 mg, 59% yield) was synthesized from **21d** (15.9 mg, 0.0372 mmol) in the same manner as **11a**. $[\alpha]_D^{26} = -41.8$ (c 1.0 in pyridine); ¹H NMR (CDCl₃, 400 MHz): δ 8.00-7.90 (m, 4H), 7.65 (d, *J* = 8.5 Hz, 1H), 7.55-7.47 (m, 2H), 4.72 (s, 2H), 4.54 (d, *J* = 9.9 Hz, 1H), 4.45-3.97 (m, 7H), 3.55 (t, *J* = 6.7 Hz, 2H), 2.94 (d, *J* = 6.3 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 1.68 (m, 2H), 1.57 (m, 2H), 1.44-1.13 (m, 14H); ¹³C NMR (CDCl₃, 100 MHz): δ 186.4, 184.7, 170.7, 169.5, 137.6, 134.2, 133.7, 128.7, 128.6, 128.5, 126.9, 126.8, 126.6, 126.5, 86.4, 80.7, 79.2, 75.8, 73.2, 71.5, 71.3,

71.0, 62.0, 50.0, 37.8, 33.3, 30.5, 30.3, 30.1, 30.1, 30.0, 29.8, 29.4, 26.9; HRMS (ESI) m/z $[M+H]^+$ calculated for C₃₄H₄₉N₂O₉S 661.3159, found 661.3153

13-(Naphthalen-2-ylmethoxy)tridecan-1-ol (13e)

13e (white solid, 492 mg, 46% yield) was synthesized from **12b** (675 mg, 2.82 mmol) in the same manner as **13a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.84 (m, 3H), 7.81 (s, 1H), 7.52-7.47 (m, 3H), 4.69 (s, 2H), 3.61 (t, *J* = 6.7 Hz, 2H), 3.53 (t, *J* = 6.7 Hz, 2H), 1.72-1.65 (m, 2H), 1.60-1.53 (m, 2H), 1.44-1.29 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.0, 133.1, 132.8, 127.9, 127.6, 127.5, 126.1, 125.8, 125.5, 72.7, 70.3, 32.6, 29.6, 29.4, 29.3, 29.3, 26.0, 25.6; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₄H₃₆O₂Na 379.2613, found 379.2609

2-(((13-Bromotridecyl)oxy)methyl)naphthalene (14e)

14e (white solid, 453 mg, 82% yield) was synthesized from **13e** (475 mg, 1.25 mmol) in the same manner as **14a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.84-7.82 (m, 3H), 7.78 (s, 1H), 7.48-7.46 (m, 3H), 4.67 (s, 2H), 3.51 (t, *J* = 6.7 Hz, 2H), 3.41 (t, *J* = 6.7 Hz, 2H), 1.89-1.82 (m, 2H), 1.68-1.61 (m, 2H), 1.44-1.25 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.2, 133.2, 132.9, 128.0, 127.8, 127.6, 126.2, 126.0, 125.7, 125.7, 72.9, 70.5, 34.0, 32.8, 29.7, 29.5, 29.5, 29.4, 29.4, 28.7, 28.1, 26.2; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₄H₃₅BrONa 441.1769, 443.1749 found 441.1772, 443.1755

(S)-2-(2-((*tert*-Butyldimethylsilyl)oxy)-3-((13-(naphthalen-2-ylmethoxy)tridecyl)thio)propyl)isoi ndoline-1,3-dione (19e)

19e (colorless oil, 434 mg, 74% yield) was synthesized from **14e** (363 mg, 0.823 mmol) in the same manner as **19a**. $[\alpha]_D^{26} = -24.4$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.87-7.81 (m, 5H), 7.78 (s, 1H), 7.73-7.69 (m, 2H), 7.49-7.44 (m, 3H), 4.67 (s, 2H), 4.18 (m, 1H), 3.94-3.78 (m, 2H), 3.51 (t, *J* = 6,7 Hz, 2H), 2.64 (t, *J* = 7.2 Hz, 2H), 2.56 (t, *J* = 7.2 Hz, 2H), 1.68-1.52 (m, 4H), 1.40-1.23 (m, 18H), 0.807 (s, 9H), 0.0514 (s, 3H), -0.119 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.2, 136.2, 133.9, 133.2, 132.9, 132.0, 128.0, 127.8, 127.6, 126.2, 125.9, 125.7, 125.7, 123.1, 72.9, 70.5, 69.1, 43.1, 37.4, 33.0, 29.7, 29.6, 29.5, 29.4, 29.2, 28.8, 26.1, 25.6, 17.7, -4.6, -4.9; HRMS (ESI) m/z [M+H]⁺ calculated for C₄₁H₆₀NO₄SSi 690.4012, found 690.4009

(S)-2-(2-Hydroxy-3-((13-(naphthalen-2-ylmethoxy)tridecyl)thio)propyl)isoindoline-1,3-dione (20e)

20e (colorless oil, 348 mg, 61% yield) was synthesized from **19e** (679 mg, 0.954 mmol) in the same manner as **20a**. $[\alpha]_D{}^{26} = 3.60$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.87-7.81 (m, 5H), 7.77 (s, 1H), 7.74-7.70 (m, 2H), 7.49-7.44 (m, 3H), 4.66 (s, 2H), 4.03 (m, 1H), 3.85-3.84 (m, 2H), 3.50 (t, J = 6.7 Hz, 2H), 2.78-2.56 (m, 2H), 2.54 (t, J = 7.2 Hz, 2H), 1.67-1.53 (m, 4H),

1.40-1.24 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.0, 133.9, 133.1, 132.7, 131.7, 127.9, 127.7, 127.5, 126.1, 125.8, 125.6, 123.2, 72.7, 70.4, 68.1, 42.8, 37.3, 32.5, 29.6, 29.5, 29.4, 29.3, 29.0, 28.6, 26.0; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₅H₄₆NO₄S 576.3148, found 576.3145

(S)-1-Amino-3-((13-(naphthalen-2-ylmethoxy)tridecyl)thio)propan-2-ol (21e)

21e (white solid, 48.0 mg, 94% yield) was synthesized from **20e** (65.2 mg, 0.109 mmol) in the same manner as **21a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.83-7.81 (m, 3H), 7.78 (s, 1H), 7.48-7.46 (m, 3H), 4.66 (s, 2H), 3.64 (m, 2H), 3.50 (t, J = 6.7 Hz, 2H), 2.89-2.85 (dd, J = 3.2, 13.0 Hz, 1H), 2.69-2.56 (m, 3H), 2.51 (t, J = 7.2 Hz, 2H), 1.67-1.53 (m, 4H), 1.41-1.24 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.1, 133.2, 132.8, 128.0, 127.8, 127.6, 126.2, 125.9, 125.7, 125.6, 72.8, 70.5, 70.3, 46.3, 37.0, 32.4, 29.7, 29.6, 29.5, 29.4, 29.4, 29.1, 28.8, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₇H₄₄NO₂S 446.3093, found 446.3084

3-(((S)-2-Hydroxy-3-((13-(naphthalen-2-ylmethoxy)tridecyl)thio)propyl)amino)-4-(glucosylami no)cyclobut-3-ene-1,2-dione (11e)

11e (white solid, 35.0 mg, 89% yield) was synthesized from **21e** (25.4 mg, 0.0542 mmol) in the same manner as **11a**. $[\alpha]_D^{26} = -48.6$ (c 1.0 in pyridine); ¹H NMR (pyridine-d₅, 400 MHz): δ 8.10-7.90 (m, 4H), 7.64 (d, J = 8.5 Hz, 1H), 7.52-7.48 (m, 2H), 4.72 (s, 2H), 4.52 (d, J = 11.2 Hz, 1H), 4.43-3.97 (m, 7H), 3.55 (t, J = 6.3 Hz, 2H), 2.94 (d, J = 4.9 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 1.70 (m, 2H), 1.58 (m, 2H), 1.48-1.17 (m, 20H); ¹³C NMR (pyridine-d₅, 100 MHz): δ 186.3, 184.6, 170.6, 169.4, 137.6, 134.2, 133.7, 128.7, 128.5, 128.5, 126.9, 126.8, 126.6, 126.5, 86.3, 80.6, 79.1, 75.7, 73.2, 71.4, 71.2, 71.0, 62.0, 50.0, 37.8, 33.3, 32.4, 30.5, 30.3, 30.2, 30.1, 30.1, 29.8, 29.5, 26.9; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₇H₅₅N₂O₉S 703.3628, found 703.3628

15-(Naphthalen-2-ylmethoxy)pentadecan-1-ol (13f)

13f (yellow oil, 350 mg, 27% yield) was synthesized from **12c** (851 mg, 3.18 mmol) in the same manner as **13a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.84-7.82 (m, 2H), 7.78 (s, 1H), 7.49-7.45 (m, 3H), 4.67 (s, 2H), 3.63 (t, *J* = 6.7 Hz, 2H), 3.51 (t, *J* = Hz, 2H), 1.68-1.53 (m, 4H), 1.28 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.2, 133.2, 132.9, 128.0, 127.8, 127.6, 126.2, 125.9, 125.7, 125.7, 72.9, 70.5, 63.0, 32.7, 29.7, 29.6, 29.5, 29.4, 29.4, 29.4, 26.1, 25.7; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₆H₄₀O₂Na 407.2926, found 407.2923

2-(((15-Bromopentadecyl)oxy)methyl)naphthalene (14f)

14f (white solid, 268 mg, 47% yield) was synthesized from **13f** (495 mg, 1.22 mmol) in the same manner as **14a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.83 (m, 3H), 7.80 (s, 1H), 7.51-7.47 (m, 3H), 4.69 (s, 2H), 3.53 (t, *J* = 6.7 Hz, 2H), 3.41 (t, *J* = 7.2 Hz, 2H), 1.90-1.83 (m, 2H), 1.71-1.63 (m, 2H),

1.45-1.29 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.0, 133.1, 132.7, 127.8, 127.6, 127.4, 125.9, 125.7, 125.5, 72.7, 70.3, 33.6, 32.6, 29.6, 29.5, 29.4, 29.4, 29.3, 29.3, 28.6, 28.0, 26.0; HRMS (ESI) m/z [M+Na]⁺ calculated for C₂₆H₃₉BrONa 469.2082, 471.2062, found 469.2081, 471.2062

(S)-2-(2-((*tert*-Butyldimethylsilyl)oxy)-3-((15-(naphthalen-2-ylmethoxy)pentadecyl)thio)propyl) isoindoline-1,3-dione (19f)

19f (yellow oil, 300 mg, 60% yield) was synthesized from **14f** (317 mg, 0.675 mmol) in the same manner as **19a**. $[\alpha]_D{}^{26} = -25.6$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.81 (m, 3H), 7.78 (s, 1H), 7.48-7.45 (m, 3H), 4.66 (s, 2H), 4.18 (m, 1H), 3.94-3.78 (m, 2H), 3.50 (t, *J* = 6.7 Hz, 2H), 2.64 (t, *J* = 7.6 Hz, 2H), 2.56 (t, *J* = 7.2 Hz, 2H), 1.68-1.53 (m, 4H), 1.37-1.26 (m, 22H), 0.812 (s, 9H), 0.0560 (s, 3H), -0.114 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.0, 133.6, 133.0, 132.7, 131.8, 127.8, 127.6, 127.4, 125.9, 125.7, 125.5, 122.8, 72.7, 70.3, 69.0, 42.9, 37.3, 32.8, 29.6, 29.4, 29.4, 29.3, 29.3, 29.0, 28.6, 26.0, 25.4; HRMS (ESI) m/z [M+H]⁺ calculated for C₄₃H₆₄NO₄SSi 718.4325, found 718.4318

(S)-2-(2-Hydroxy-3-((15-(naphthalen-2-ylmethoxy)pentadecyl)thio)propyl)isoindoline-1,3-dion e (20f)

20f (white solid, 120 mg, 79% yield) was synthesized from **19f** (180 mg, 0.242 mmol) in the same manner as **20a**. $[\alpha]_D^{26} = 2.80$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.87-7.82 (m, 5H), 7.78 (s, 1H), 7.75-7.71 (m, 2H), 7.52-7.46 (m, 3H), 4.67 (s, 2H), 4.04 (m, 1H), 3.85 (m, 2H), 3.51 (t, *J* = 6.7 Hz, 2H), 2.78-2.53 (m, 4H), 1.66-1.54 (m, 4H), 1.42-1.24 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.1, 133.9, 133.2, 132.8, 131.8, 127.9, 127.7, 127.5, 126.1, 125.9, 125.6, 123.3, 72.8, 70.4, 68.2, 42.9, 37.4, 32.5, 42.9, 37.4, 32.5, 29.7, 29.6, 29.5, 29.5, 29.4, 29.1, 28.7, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₇H₅₀NO₄S 604.3461, found 604.3453

$(S) \hbox{-} 1-Amino \hbox{-} 3-((15-(naphthalen-2-ylmethoxy)pentadecyl) thio) propan-2-ol~(21f)$

21f (white solid, 69.0 mg, quant.) was synthesized from **20f** (87.0 mg, 0.139 mmol) in the same manner as **21a**. ¹H NMR (CDCl₃, 400 MHz): δ 7.83-7.81 (m, 3H), 7.77 (s, 1H), 7.48-7.45 (m, 3H), 4.66 (s, 2H), 3.63 (m, 1H), 3.50 (t, *J* = 6.7 Hz, 2H), 2.86 (dd, *J* = 3.1, 12.5 Hz, 1H), 2.69-2.51 (m, 5H), 1.67-1.54 (m, 4H), 1.41-1.24 (m, 22H); ¹³C NMR (CDCl₃, 100 MHz): δ 136.1, 133.2, 132.8, 128.0, 127.7, 127.6, 126.1, 125.9, 125.7, 125.6, 72.8, 70.5, 70.3, 46.3, 37.0, 32.4, 29.7, 29.6, 29.5, 29.5, 29.4, 29.4, 29.1, 28.8, 26.1; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₉H₄₈NO₂S 474.3406, found 474.3404

3-(((S)-2-Hydroxy-3-((15-(naphthalen-2-ylmethoxy)pentadecyl)thio)propyl)amino)-4-(glucosyla mino)cyclobut-3-ene-1,2-dione (11f)

11f (white solid, 44.0 mg, 95% yield) was synthesized from **21f** (30.5 mg, 0.0614 mmol) in the same manner as **11a**. $[\alpha]_D^{26} = -47.4$ (c 1.0 in pyridine); ¹H NMR (pyridine-d₅, 400 MHz): δ 8.00-7.91 (m, 4H), 7.64 (d, J = 8.1 Hz, 1H), 7.54-7.47 (m, 2H), 4.72 (s, 2H), 4.53 (d, J = 9.4 Hz, 1H), 4.44-3.97 (m, 7H), 3.56 (t, J = 6.7 Hz, 2H), 2.94 (d, J = 6.3 Hz, 2H), 2.65 (t, J = 7.2 Hz, 2H), 1.70 (m, 2H), 1.59 (m, 2H), 1.48-1.17 (m, 24H); ¹³C NMR (pyridine- d₅, 100 MHz): δ 186.4, 184.7, 170.6, 169.4, 137.6, 134.2, 133.7, 128.7, 128.6, 128.5, 126.9, 126.8, 126.6, 126.5, 86.4, 80.7, 79.2, 75.8, 73.2, 71.5, 71.2, 71.0, 62.0, 50.0, 37.8, 33.4, 30.5, 30.3, 30.3, 30.2, 30.2, 30.1, 29.9, 26.9; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₉H₅₉N₂O₉S 731.3941, found 731.3936

2-((S)-2-((*tert*-Butyldimethylsilyl)oxy)-3-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)thio)pro pyl)isoindoline-1,3-dione (19g)

19g (colorless oil, 160 mg, 61% yield) was synthesized from **17**^[2] (152 mg, 0.406 mmol) in the same manner as **19a**. $[\alpha]_D^{26} = -11.4$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.84-7.67 (m, 4H), 5.35 (m, 8H), 4.16 (m, 1H), 3.91-3.76 (m, 2H), 2.81 (m, 6H), 2.62 (t, *J* = 6.7 Hz, 2H), 2.56 (t, *J* = 7.2 Hz, 2H), 2.04 (m, 4H), 1.58 (m, 2H), 1.43 (m, 2H), 1.37-1.22 (m, 6H), 0.868 (t, *J* = 6.7 Hz, 3H), 0.789 (s, 9H), 0.0342 (s, 3H), -0.135 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.1, 133.8, 132.0, 130.3, 129.6, 128.4, 128.2, 127.9, 127.8, 127.4, 123.0, 69.1, 43.0, 37.4, 32.8, 31.4, 29.2, 29.1, 28.6, 27.1, 26.7, 25.5, 22.4, 17.6, 14.0, -4.7, -5.0; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₇H₅₇NO₃SSiNa 646.3726, found 646.3720

2-((S)-2-Hydroxy-3-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)thio)propyl)isoindoline-1,3-d ione (20g)

20g (yellow oil, 41.0 mg, 88% yield) was synthesized from **19g** (56.6 mg, 0.0875 mmol) in the same manner as **20a**. $[\alpha]_D^{26} = 0.160$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.89-7.69 (m, 4H), 5.34 (m, 8H), 4.03 (m, 1H), 3.85 (m, 2H), 2.88-2.58 (m, 8H), 2.56 (t, J = 7.2 Hz, 2H), 2.05 (m, 4H), 1.60 (m, 2H), 1.45 (m, 2H), 1.38-1.23 (m, 6H), 0.877 (t, J = 7.2 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.6, 134.0, 131.9, 130.4, 129.6, 128.5, 128.2, 128.1, 128.0, 127.8, 127.5, 123.4, 68.2, 42.9, 37.4, 32.5, 31.4, 29.2, 29.2, 28.6, 21.1, 26.7, 25.6, 22.5, 14.0; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₁H₄₃NO₃SNa 532.2861, found 532.2879

(S)-1-Amino-3-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)thio)propan-2-ol (21g)

To a solution of **20g** (19.0 mg, 0.0373 mmol) in MeOH (373 µL) was added methyl hydrazine^[3] (12.0 µL, 0.373 mmol). The mixture was refluxed for 2.5h. After evaporation under vacuum, the crude product was purified using column chromatography (silica gel, CHCl₃ / MeOH = 20 / 1 containing 1% (v/v) Et₃N) to afford **21g** (colorless oil, 15.0 mg, quant.). ¹H NMR (CDCl₃, 400 MHz): δ 5.39 (m, 8H), 4.01 (br, 1H), 3.22-2.88 (m, 2H), 2.82 (m, 6H), 2.64 (m, 2H), 2.53 (t, *J* = 7.2

Hz, 2H), 2.06 (m, 4H), 1.63-1.22 (m, 10H), 0.884 (t, J = 6.3 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 130.4, 129.6, 128.5, 128.2, 128.1, 128.1, 127.8, 127.5, 67.7, 44.6, 36.6, 31.5, 29.3, 29.2, 28.7, 27.2, 26.7, 25.6, 22.5, 14.0; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₃H₄₂NOS 380.2987, found 380.2983

3-(((S)-2-Hydroxy-3-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)thio)propyl)amino)-4-(gluco sylamino)cyclobut-3-ene-1,2-dione (11g)

11g (yellow oil, 10.0 mg, 67% yield) was synthesized from **21g** (9.10 mg, 0.0226 mmol) in the same manner as **11a**. $[\alpha]_D^{26} = -57.0$ (c 1.0 in pyridine); ¹H NMR (pyridine-d₅, 400 MHz): δ 5.56-5.40 (m, 8H), 4.52 (d, J = 9.9 Hz, 1H), 4.44-3.98 (m, 8H), 3.10-2.90 (m, 8H), 2.65 (t, J = 7.2 Hz, 2H), 2.11 (m, 4H), 1.62 (m, 2H), 1.47-1.21 (m, 8H), 0.855 (t, J = 6.7 Hz, 3H); ¹³C NMR (pyridine-d₅, 100 MHz): δ 186.3, 184.7, 170.7, 169.5, 131.0, 130.5, 129.2, 129.1, 128.7, 128.7, 128.6, 128.4, 86.3, 80.7, 79.2, 75.7, 71.5, 71.3, 62.1, 50.0, 37.8, 33.2, 32.0, 29.9, 29.9, 29.4, 26.3, 23.2, 23.1, 14.5; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₃H₅₃N₂O₈S 637.3523, found 637.3520

(S)-2-(Thiiran-2-ylmethyl)isoindoline-1,3-dione (23)

To a solution of **22**^[1] (2.90 g, 0.0143 mol) in MeOH (48 mL) was added thiourea^[4] (2.20 g, 0.0285 mol). The mixture was stirred at ambient temperature for 22 h. After evaporation under vacuum, the crude product was purified using column chromatography (silica gel, hexane / EtOAc = 6 / 1) to afford **23** (white solid, 2.33 g, 74% yield). $[\alpha]_D^{26} = 1.56$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.85-7.81 (m, 2H), 7.74-7.70 (m, 2H), 4.12 (dd, J = 4.5, 14 Hz, 2H), 3.59 (dd, J = 7.2, 14 Hz, 2H), 3.13 (m, 1H), 2.45 (d, J = 5.8 Hz, 1H), 2.41 (d, J = 4.9 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz): δ 167.8, 134.0, 131.7, 123.3, 42.8, 30.9, 24.6; HRMS (ESI) m/z [M+H]⁺ calculated for C₁₁H₁₀NO₂S 220.0432, found 220.0425

(S)-2-(Acetylthio)-3-(1,3-dioxoisoindolin-2-yl)propyl acetate (24)

To a solution of **23** (1.90 g, 0.00867 mol) and sodium acetate (142 mg, 0.00173 mol) in acetic anhydride (36 mL) was added acetic acid (3.6 mL). The mixture was refluxed for 38 h. After evaporation under vacuum, the crude product was purified using column chromatography (silica gel, hexane / EtOAc = 8 / 1 to 4 / 1) to afford **24** (brown oil, 1.89 g, 68% yield). $[\alpha]_D^{26}$ = -26.4 (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.82-7.80 (m, 2H), 7.70-7.68 (m, 2H), 4.26-4.12 (m, 3H), 3.97-3.87 (m, 2H), 2.24 (s, 3H), 2.01 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 193.6, 170.3, 167.7, 134.0, 131.6, 64.1, 41.6, 38.3, 30.4, 20.5; HRMS (ESI) m/z [M+Na]⁺ calculated for C₁₅H₁₅NO₅SNa 344.0569, found 344.0564

(S)-2-(3-Hydroxy-2-mercaptopropyl)isoindoline-1,3-dione (25)

To a solution of **24** (512 mg, 1.59 mmol) in MeOH (6 mL) was added 4 N HCl/dioxane (2 mL). The mixture was stirred at ambient temperature for 2 h. After evaporation under vacuum, the crude product was purified using column chromatography (silica gel, hexane / EtOAc = 4 / 1 to 2 / 1) to afford **25** (white solid, 313 mg, 83% yield). $[\alpha]_D^{26} = -42.4$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.85-7.82 (m, 2H), 7.75-7.72 (m, 2H), 3.90 (m, 2H), 3.71-3.59 (m, 2H), 3.19 (m, 1H), 3.07 (m, 1H), 1.72 (d, *J* = 9.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.6, 134.2, 131.5, 123.5, 64.4, 40.9, 40.7; HRMS (ESI) m/z [M+Na]⁺ calculated for C₁₁H₁₁NO₃SNa 260.0357, found 260.0359

(S)-2-(3-Hydroxy-2-(icosylthio)propyl)isoindoline-1,3-dione (26a)

26a (white solid, 79.0 mg, 73% yield) was synthesized from **25** (52.0 mg, 0.200 mmol) in the same manner as **19a**. $[\alpha]_D{}^{26} = -1.78$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.87-7.84 (m, 2H), 7.74-7.72 (m, 2H), 3.99-3.88 (m, 2H), 3.64 (m, 2H), 3.14 (m, 1H), 2.60 (t, J = 2.6 Hz, 2H), 1.56 (t, J = 7.6 Hz, 2H), 1.25 (m, 34H), 0.869 (t, J = 6.3 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.6, 134.1, 131.8, 123.4, 62.2, 47.1, 38.4, 31.9, 30.9, 29.6, 29.4, 29.3, 29.1, 28.8, 22.6, 14.1; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₁H₅₁NO₃SNa 540.3487, found 540.3483

(S)-3-Amino-2-(icosylthio)propan-1-ol (27a)

27a (white solid, 72.0 mg, 97% yield) was synthesized from **26a** (97.7 mg, 0.181 mmol) in the same manner as **21a**. ¹H NMR (CDCl₃, 400 MHz): δ 3.80-3.71 (m, 2H), 3.03-2.91 (m, 2H), 2.79 (m, 1H), 2.52 (t, *J* = 7.2 Hz, 2H), 1.61-1.53 (m, 2H), 1.37-1.24 (m, 34H), 0.865 (t, *J* = 6.7 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 65.1, 49.9, 44.8, 31.9, 30.8, 30.0, 29.6, 29.5, 29.4, 29.3, 29.1, 28.8, 22.6, 14.0; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₃H₅₀NOS 388.3613, found 388.3610

3-(((S)-3-Hydroxy-2-(icosylthio)propyl)amino)-4-(glucosylamino)cyclobut-3-ene-1,2-dione (11h)

11h (white solid, 23.0 mg, 72% yield) was synthesized from **27a** (19.6 mg, 0.0479 mg) in the same manner as **11a**. $[\alpha]_D{}^{26} = -6.40$ (c 1.0 in pyridine); ¹H NMR (pyridine-d₅, 400 MHz): δ 5.11 (br, 1H), 4.75 (m, 2H), 4.65 (m, 1H), 4.35 (m, 1H), 3.59-3.34 (m, 4H), 1.46 (t, J = 7.2 Hz, 3H) ; ¹³C NMR (pyridine-d₅, 100 MHz): δ 189.4, 189.3, 179.4, 175.2, 85.0, 83.9, 82.2, 78.5, 78.2, 78.0, 74.2, 74.1, 71.0, 70.0, 69.9, 16.0; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₃H₆₀N₂O₈SNa 667.3968, found 667.3972

2-((S)-3-Hydroxy-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)thio)propyl)isoindoline-1,3-d ione (26b)

26b (colorless oil, 90.3 mg, 75% yield) was synthesized from **17** (84.9 mg, 0.226 mmol) in the same manner as **19a**. $[\alpha]_D^{26} = -8.32$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 7.86-7.82 (m,

2H), 7.78-7.68 (m, 2H), 5.35 (m, 8H), 3.93 (m, 2H), 3.63 (m, 2H), 3.13 (m, 1H), 2.79 (m, 6H), 2.62 (t, J = 7.2 Hz, 2H), 2.04 (m, 4H), 1.59 (m, 2H), 1.51-1.20 (m, 8H), 0.869 (t, J = 6.7 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 168.5, 134.1, 131.7, 130.4, 129.5, 128.4, 128.2, 128.1, 128.0, 127.8, 127.4, 123.4, 62.2, 47.1, 38.3, 31.4, 30.7, 29.2, 29.2, 28.6, 27.1, 26.6, 25.5, 22.5, 14.0; HRMS (ESI) m/z [M+K]⁺ calculated for C₃₁H₄₃NO₃SK 548.2601, found 548.2615

(S)-3-Amino-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)thio)propan-1-ol (27b)

27b (colorless oil, 6.73 mg, 92% yield) was synthesized from **26b** (10.0 mg, 0.0193 mmol) in the same manner as **21a**. $[\alpha]_D^{26} = -2.60$ (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, 400 MHz): δ 5.36 (m, 8H), 3.82-3.70 (m, 2H), 3.04-2.77 (m, 9H), 2.53 (t, J = 7.2 Hz, 2H), 2.05 (m, 4H), 1.59 (m, 2H), 1.45 (m, 2H), 1.37-1.24 (m,4H), 0.875 (t, J = 6.7 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 130.4, 129.5, 128.5, 128.1, 128.0, 127.8, 127.4, 64.9, 49.5, 44.4, 31.4, 30.7, 29.5, 29.2, 28.7, 27.1, 26.7, 25.5, 22.5, 14.0; HRMS (ESI) m/z [M+H]⁺ calculated for C₂₃H₄₂NOS 380.2987, found 380.2986

3-(((S)-3-Hydroxy-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl)thio)propyl)amino)-4-(gluco sylamino)cyclobut-3-ene-1,2-dione (11i)

11i (colorless oil, 9.00 mg, 60% yield) was synthesized from **27b** (9.15 mg, 0.0228 mmol) in the same manner as **11a**. $[\alpha]_D{}^{26} = -41.0$ (c 1.0 in pyridine); ¹H NMR (pyridine-d₅, 400 MHz): δ 5.58-5.40 (m,8H), 4.56-4.04 (m, 10H), 3.36 (br, 1H), 2.95 (m, 6H), 2.74 (m, 2H), 2.09 (m, 4H), 1.64 (m, 2H), 1.50-1.20 (m, 8H), 0.852 (t, J = 6.7 Hz, 3H); ¹³C NMR (pyridine-d₅, 100 MHz): δ 186.3, 184.6, 170.3, 169.4, 130.9, 130.6, 129.1, 129.1, 128.7, 128.7, 128.6, 128.3, 86.5, 80.6, 79.1, 75.8, 70.9, 63.5, 61.8, 50.5, 46.0, 31.9, 31.6, 30.3, 30.3, 29.8, 29.4, 27.7, 26.3, 23.1, 14.5; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₃H₅₂N₂O₈SNa 659.3342, found 659.3342

3-Ethoxy-4-(6-(fluoromethyl)glucosylamino)cyclobut-3-ene-1,2-dione (28b)

28b (brown oil, 40.0 mg, 83% yield) was synthesized from 6-deoxy-6-fluoro-β-D-glucopyranose (26.8 mg, 0.147 mmol) in the reported method.^[1] [α]_D²⁶ = -11.2 (c 1.0 in MeOH); ¹H NMR (CD₃OD, 400 MHz): δ 4.75 (q, *J* = 7.2 Hz, 2H), 4.66 (m, 1H), 4.53 (m, 1H), 3.56-3.35 (m, 5H), 1.46 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CD₃OD, 100 MHz): δ 189.4, 189.3, 179.4, 175.2, 83.9, 82.2, 78.5, 78.2, 78.0, 74.2, 74.1, 71.0, 70.0, 69.9, 16.0; HRMS (ESI) m/z [M+Na]⁺ calculated for C₁₂H₁₆FNO₇Na 328.0807, found 328.0808

3-(6-(Fluoromethyl)glucosylamino)-4-(((S)-2-hydroxy-3-(octadecylthio)propyl)amino)cyclobut-3-ene-1,2-dione (11j)

11j (yellow oil, 5.40 mg, 42% yield) was synthesized from **28b** (6.58 mg, 0.0200 mmol) in the same manner as **11a.** $[\alpha]_D^{26} = -10.0$ (c 1.0 in pyridine); ¹H NMR (pyridine- d₅, 400 MHz): δ 4.32-3.85 (m,

8H), 2.89 (m, 2H), 2.63 (t, J = 7.2 Hz, 2H), 1.63-1.54 (m, 2H), 1.41-1.18 (m, 32H), 0.876 (t, J = 6.7 Hz, 3H); ¹³C NMR (pyridine- d₅, 100 MHz): δ 186.0, 184.4, 169.6, 168.1, 86.1, 84.5, 82.7, 79.1, 78.2, 78.0, 75.3, 71.1, 70.9, 70.2, 70.1, 66.1, 49.8, 37.5, 33.3, 32.4, 30.3, 30.2, 29.9, 29.9, 29.5, 23.2, 14.6; HRMS (ESI) m/z [M+H]⁺ calculated for C₃₁H₅₆N₂O₇FS 619.3792, found 619.3795

3-((1-Hydroxy-2-(hydroxymethyl)icosan-2-yl)amino)-4-(glucosylamino)cyclobut-3-ene-1,2-dion e (11k)

To a solution of **28a**^[1] (26.0 mg, 0.0873 mmol) and 2-amino-2-octadecylpropane-1,3-diol^[5] (30.0 mg, 0.0873 mmol) in EtOH (873 µL) was added DIPEA (15.0 µL, 0.0873 mmol). The mixture was stirred at 70 °C for 14.5 h. After evaporation under vacuum, the crude product was purified using column chromatography (silica gel, chloroform / methanol = 10 / 1 \rightarrow 5 / 1) to afford **11k** (white solid, 19.0 mg, 36% yield). [α]_D²⁶ = 0.400 (c 1.0 in pyridine); ¹H NMR (pyridine- d₅, 400 MHz): δ 4.50-4.09 (m, 11H), 2.30 (m, 2H), 1.48 (m, 2H), 1.32-1.10 (m, 30H), 0.828 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (pyridine- d₅, 100 MHz): δ 184.3, 184.0, 170.7, 86.1, 80.8, 79.5, 75.6, 71.5, 65.1, 65.1, 63.4, 62.7, 34.3, 32.4, 31.0, 30.3, 30.2, 29.9, 24.1, 23.2, 14.6; HRMS (ESI) m/z [M+Na]⁺ calculated for C₃₁H₅₆N₂O₉Na 623.3884, found 623.3880

References

- F. Ding, A. T. Guy, P. Greimel, Y. Hirabayashi, H. Kamiguchi, Y. Ito, *Chem. Commun.* 2018, 54, 8470-8473.
- [2] (a) C. J. Easton, L. Xia, M. J. Pitt, A. Ferrante, A. Poulos, D. A. Rathjen, *Synthesis*, 2001, *3*, 451-457. (b) G. M. Maharvi, A. O. Edwards and A. H. Fauq, *Tetrahedron Lett.* 2010, *51*, 6426–6428.
- [3] A. L. Smith, C.-K. Hwang, E. Pitsinos, G. R. Scarlato and K. C. Nicolaou, J. Am. Chem. Soc. 1992, 114, 3136-3138.
- [4] B. Tber, Nour-Eddine Fahmi, G. Ronco, P. Villa, D. F. Ewing, G. Mackenzie, *Carbohydr. Res.* 1995, 267, 203-215.
- [5] T. Fujita, R. Hirose, M. Yoneta, S. Sasaki, K. Inoue, M. Kiuchi, S. Hirase, K. Chiba, H. Sakamoto, M. Arita, J. Med. Chem. 1996, 39, 4451-4459.



2-3. ¹H and ¹³C NMR chart of compounds


























































































































































































































